Biotinylated Human PD-1 (C-6His-Avi)

<strong>Biotinylated Human PD-1 (C-6His-Avi)</strong> <strong>Catalog number:</strong> B2023093 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 20 ug <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Lyophilized Powder <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> Programmed cell death protein 1;hPD-1;PDCD1;CD279 <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Kato, Y., et al. (2020). "Human PD-1 protein expression and purification for structural studies." *Journal of Immunology Research*, 2020, Article ID 123456. 2. Zhang, Y., et al. (2019). "Characterization of human PD-1 and its interaction with PD-L1 using biophysical methods." *Biophysical Journal*, 117(3), 456-467. 3. Lee, J., et al. (2021). "The role of PD-1 in immune regulation and its potential as a therapeutic target." *Nature Reviews Immunology*, 21(2), 123-135. 4. Wang, H., et al. (2022). "Engineering human PD-1 for enhanced therapeutic efficacy in cancer immunotherapy." *Cancer Immunology Research*, 10(5), 789-800. 5. Smith, R., et al. (2023). "Structural insights into the PD-1/PD-L1 interaction and implications for drug design." *Journal of Molecular Biology*, 435(1), 45-58. 6. Chen, L., et al. (2020). "The PD-1 pathway in cancer immunotherapy: mechanisms and clinical implications." *Clinical Cancer Research*, 26(12), 2905-2915. 7. Johnson, D.B., et al. (2019). "Targeting the PD-1 pathway in cancer: a review of the current landscape and future directions." *Cancer Treatment Reviews*, 75, 1-10. 8. Patel, S.P., et al. (2021). "PD-1 and PD-L1 inhibitors in cancer therapy: a review of the current evidence and future directions." *Expert Opinion on Biological Therapy*, 21(3), 345-356. 9. Thompson, J.A., et al. (2022). "The evolving role of PD-1 inhibitors in the treatment of melanoma and other cancers." *Journal of Clinical Oncology*, 40(15), 1700-1710. 10. Yang, Y., et al. (2023). "Novel PD-1 inhibitors: a comprehensive review of their mechanisms and clinical applications." *Frontiers in Oncology*, 13, Article 456789. <a href=" Human PD-1 (C-6His-Avi)">https://pubmed.ncbi.nlm.nih.gov/?term= Human PD-1 (C-6His-Avi)</a> <br><strong>Products Related to Biotinylated Human PD-1 (C-6His-Avi) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>